A UK firm has begun the first human trial investigating the use of genetically engineered white blood cells in treating HIV. The therapy developed by Oxford-based Adaptimmune involves the removal of some of a patient's T-cells, altering the cells' DNA to produce an enhanced version of a ...
Please Login to read the full article.
